AIm: Cyclooxygenase-2 (Cox-2) appears to play a role in the regulation of progression, invasiveness and angiogenesis of various neoplasms. Experimental studies have indicated that COX-2 regulate angiogenesis by modulating vascular endothelial growth factor (VEGF) production. The aim of this study was to evaluate the immunohistochemical expression of COX-2 in astrocytoma, in relation to VEGF expression, microvessel density (MVD), clinicopathologic factors and patient survival. mAterIAl and methOds: 26 paraffin blocks of astrocytoma, with representative tissues and sufficient follow-up data, were evaluated immunohistochemically for protein marker expression.
InTRoduCTIon
Prostaglandin H synthetase (PGHS) or COX is the rate-limiting enzyme in the synthesis of prostaglandins and thromboxane from arachidonic acid. Two isoforms of PGHS, referred to as COX-1 and COX-2, have been described (7, 38) . COX-2 expression is inducible and increases in response to various stimuli, including inflammatory signals, mitogens, cytokines, and growth factors (8, 19, 28) . Increased COX-2 expression was detected in a variety of human cancers, including pancreatic, gastric, esophageal, prostatic, lung and head and neck cancers (3, 16, 25, 35, 41, (43) (44) (45) .
The astrocytic glioma is the most common primary brain tumor, accounting for more than 25% of all central nervous system neoplasm. It ranges in clinical behavior and histological appearance from indolent and well-differentiated lesions to highly anaplastic and rapidly growing tumor. For growth, neoangiogenesis is a prerequisite, and correlations between vascular proliferation and morphological changes of the neovasculature and tumor aggressiveness have been described (12, 37) . Angiogenesis is a very complex multistep process that leads to formation of new blood vessels. It depends on the local balance between various molecules that induce and inhibit neovascularization (21) , with the vascular endothelial growth factor (VEGF) thought to be a pivotal inducer of brain tumor neoangiogenesis (17, 33, 34) . It has been shown that hypoxia; hypoglycemia, hormones, growth factors, and deregulation of several genes are responsible for upregulation of VEGF expression (17) . Furthermore, several studies have indicated that overexpression of COX-2 may contribute to VEGF-induced angiogenesis (10, 11) . It has been reported that COx-2 works on angiogenesis associated with growth and advancement of various tumors including advanced ovarian serous carcinomas, breast cancers, gastric cancers, renal cell carcinomas, head and neck squamous cell carcinoma and colon cancers (1, 4, 11, 15, 24, 39) .
The aim of the present study was to examine the immunohistochemical expression of COX-2 in relation to VEGF and microvessel density (MVD) in astrocytomas. We also analyzed the relative importance of COX-2 immunoreactive scores with other clinicopathologic features as patient age, sex, tumor location, histopathologic grade and patient survival.
MATERIAL and METHodS

Specimen collection:
A total of 26 cases of astrocytic tumor surgically treated at Neurosurgery Department, Zagazig University Hospital during the period from September 2006 to April 2008. The clinical data of the patients were obtained from medical files. They included 14 male and 12 female patients with ages ranging from 4 to 56 years with a mean age of 35.7±18.2. All patients were treated with surgery and radiation therapy. The survival period was determined from the date of initial surgery and median follow-up duration was 12.88±5.31 months.
Histopathological examination:
Tumor specimens were fixed in 10% buffered formalin and embedded in paraffin. Consecutive 4 um sections were prepared and stained with hematoxylin & eosin for histopathological examination. Pathological diagnosis of astrocytic tumor was made according to the World Health Organization (WHO) classification of brain tumors (18) . The tumors comprised 15 high grade astrocytomas, including 9 glioblastomas (grade IV) and 6 anaplastic astrocytomas (grade III), as well as 11 low-grade astrocytomas (grade II) which were further subclassified into 8 fibrillary (3 cases had small foci of gemistocytic cells) and 3 gemistocytic subtypes. All of the 26 astrocytomas were categorized as primary type.
Immunohistochemistry:
The immunohistochemical analysis was performed on formalin fixed, paraffin embedded tissue sections using standard streptavidin-biotin-peroxidase complex (ABC) methods. Briefly, after routine deparaffinization, the five microns thick sections mounted on optiplus positivecharged adhesive slides (Biogenix Co.) were treated with 0.3% hydrogen peroxide in methanol for 30 min to block endogenous peroxidase activity. Sections were then washed in phosphate buffered saline (PH 7.4) and Tris-buffer solution (PH 7.6) respectively. For COX-2, VEGF and CD34, slides were microwaved for 20 minutes for antigen retrieval, and incubated overnight at 4°C with optimal dilutions of primary antibodies. The antibodies used were anti-COX-2 mouse monoclonal antibody (1/50 dilution; Transduction Laboratories, Lexington, KY, USA), anti-VEGF rabbit polyclonal antibody (1/50 dilution; A-20 Santa Cruz, Biotechnology, Inc, Santa Cruz, CA.), and anti-CD34 mouse monoclonal antibody (1/25 dilution; QB-END/10, Novo-castra, Newcastle, UK). Sections then treated with avidin-biotin-peroxidase reagent for 30 minutes (Dako, Japan). Lastly, sections were incubated with diaminobenzidine and counter-stained with hematoxylin then cleared and mounted. To confirm COX-2 immuno-specificity, a case of a COX-2-positive colon cancer was used as a positive control. 0.01-M phosphate-buffered saline or mouse serum (500 dilutions) was supplied instead of primary antibodies as a negative control.
Assessment of COX-2 and VEGF immunoreactivity:
Scoring of the immuno-histochemical results for COX-2 and VEGF was performed according to the methods described by Hara et al (13) . Briefly, based on the proportions of immunopositive cells, five categories were defined as follows: 0, all negative; 1+, <25% positive cells; 2+, 25-49%; 3+, 50-74%; and 4+, >75%. The immuno-intensity was also sub classified into four groups as follows: 0, negative; 1+, weak; 2+, moderate; and 3+, strong. Positive controls were set as 3. Immunoreactivity scores for each case were produced by multiplication of the values for the two parameters. Immunoreactive scoring was categorized as low ≤ 3 and moderate to high ≥ 4.
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Assessment of Microvessel counting (Microvessel density):
A single microvessel was defined as any brown or brownish yellow CD34-immunostained endothelial cells. Microvessel density (MVD) was evaluated according to the method described by Ding et al (6) . The entire tumor section was scanned at low magnification (40x) to identify the area of highest vessel density (hot spot). The five most vascular areas within the tumor mass were chosen. Individual microvessels in each hot spot were then counted in a single 200x field and the average counts of the 5 fields were recorded and defined as MVD. A vessel lumen was not required for identification of a microvessel. Single cells or cell clusters were counted. Large vessels with thick muscular walls or with lumina greater than 50 um were excluded from the count.
Statistical analysis:
Statistical analysis of data for labeling indices was performed using the Mann-Whitney U test, Spearman's correlation coefficient, ANOVA test and the chi-square X2 test. The logrank test was performed to compare survival rates. The cut-off for statistical significance was set as p<0.05.
RESuLTS
COX-2 expression and its correlation with clinico-pathologic factors:
Cox-2 expression was confined to the cytoplasm of tumor cells. It is expressed in nerve cell bodies, in reactive astroglial cells and rarely expressed in endothelial cells. It is consistently negative in glial cells in normal brain tissue. COX-2 expression was detected in 21(80.7%) of 26 astrocytomas. Seven (63.6%) of low grade astrocytoma (N=11) had immunoreactive score ≤ 3 ( Figure 1 ) and 4 cases (36.4%) were negative. In anaplastic astrocytoma specimens (N=6), 5 cases (83.3%) had immunoreactive score≤ 3 ( Figure 2 ) and one case (16.7%) was negative. In glioblastoma specimens (N=9), 55.6% (N=5) had immunoreactive score ≥ 4 ( Figure 3 ) and 44.4% (N=4) had immunoreactive score ≤ 3. Although COX-2 staining was evident in cells located away from necrotic areas, accumulation of COX-2-positive tumor cells was particularly conspicuous around areas of necrosis (Figure 4) . The correlation between Cox-2 expression and clinicopathologic factors is shown in Table  (I, II) . COX-2 expression showed a stepwise increase from low-grade to high grade astrocytomas ( Figure 11 ) which is statistically significant (p<0.001), (r=0.64). However, COX-2 expression did not show significant difference among patient age, sex and tumor location (p>0.05).
VEGF expression and its correlation with clinicopathologic factors:
VEGF expression was confined to the cytoplasm of tumor cells. It is expressed weakly in nerve cell bodies and in reactive astroglial cells and is consistently negative in glial cells in normal brain tissue. VEGF expression was detected in 22 (84.6%) of 26 astrocytomas, including eight cases (72.7%) of low grade astrocytoma (N=11), 5 cases (83.3%) of anaplastic astrocytoma specimens (N=6) and 9 cases (100%) 0f glioblastoma specimens (N=9). In low grade astrocytoma, seven of the eight positive cases (87.5%) had immunoreactive score ≤ 3 ( Figure 5 ) and one case (12.5%) had an immunoreactive score ≥ 4. In anaplastic astrocytoma specimens, 4 of the 5 positive cases (80%) had an immunoreactive score ≤ 3 and one case (20%) had an immunoreactive score ≥ 4 ( Figure 6 ). In glioblastoma specimens, 3 of the 9 positive cases (33.3%) had an immunoreactive score ≤ 3 and 6 case (66.6%) had an immunoreactive score ≥ 4 ( Figure 7) . VEGF expression showed stepwise increase from low-grade to high-grade astrocytomas which is statistically significant (p<0.001), but did not show significant difference among patient age, sex and tumor location (p>0.05) as shown in Table (I) .
Microvessel density and its correlation with clinicopathologic factors:
The positive expression of CD34 was mainly confined to the cytoplasm of vascular endothelial cells as brownish yellow Abbreviations :
LGA ; low grade astrocytoma, AA ; anaplastic astrocytoma GBM ; glioblastoma, RT ; radiotherapy Table (I) .
Correlation between Cox-2 expression, VEGF expression and MVD:
Immunoreactive scores of VEGF positive cells were significantly increased in Cox-2 positive tumors compared with Cox-2 negative one (p<0.001), (r=0.61) as shown in Table  (III) Table  ( IV) and ( Figure 13 ). VEGF expression was also significantly correlated with MVD (p< 0.001).
Correlation between Cox-2 and patient survival:
Mean follow-up duration in COX-2 positive astrocytomas with immunoreactive scores ≥ 4 and with immunoreactive scores ≤ 3 was 7.33±3.08 and 13.73±4.48 respectively, while mean follow-up duration in COX-2 negative astrocytomas was 17±4.9. COX-2 expression was significantly correlated with poor survival (p<0.001), (r=0.58) as shown in Table (V) and (Figure 14) .
dISCuSSIon
Many glioblastomas, the most malignant type of gliomas, are believed to arise by progression from low-grade astrocytomas and anaplastic astrocytomas (35) . However, the molecular mechanisms underlying the malignant phenotype and progression are not clear (2) . There are some suggestions that COX-2 may be involved in the regulation of progression, invasiveness and angiogenesis of various neoplasms (27) . Whereas experimental studies have indicated that COX-2 regulates angiogenesis by modulating VEGF production (22), little is known about the relationships among expression of these markers.
In the present study, COX-2 expression was detected in 21(80.7%) of 26 astrocytomas. This incidence is slightly lower than that obtained by Shono et al, (35) , Lee et al, (20) and Marina et al, (22) who detected COX-2 expression in 84%, 100% and 95% respectively. In the study of Perdiki et al COX-2 expression was detected in 79 cases (95%) with an increased expression in grade IV as compared to grades II/III (29). On the other hand, our incidence is higher than that obtained by Yamen et al. (36) in which COX-2 expression was detected in 49% of astrocytomas. The discrepancies observed in these results may be related to patient selection bias and lack of standard immunohistochemical assays, including different properties of the antibodies and assessment methods of COX-2 immunoreactivity.
In our study, COX-2 expression showed significant stepwise increase from low-grade (63.6%) to high grade astrocytomas including anaplastic astrocytoma (83.3%) and glioblastoma specimens (100%). The positive association between the extent of COX-2 expression and histopathologic grade of astrocytic gliomas is consistent with that reported in other studies (13, 14, 20, 26, 35) . These observations support the hypothesis that COX-2 protein may play a relevant role in malignant change during astrocytic tumorigenesis. Although the mechanisms remain unclear, an in vitro study indicated that overexpression of COX-2 results in dedifferentiation, adhesion to extracellular matrices, and inhibition of programmed cell death in intestinal cells (11) . There are some suggestions that COX-2 may be involved with modulating several tumor related processes. Subbaramaiah et al. (36) noted that the wild type of tumor suppressor p53 gene might be responsible in part for inhibiting COX-2 gene expression, while increased amounts of bcl-2 protein were correlated with increased COX-2 expression. Epidermal growth factor (EGF) is known to up-regulate the expression of the COX-2 enzyme in several cell types, such as human squamous carcinoma cells. Among the genetic change that are commonly observed in glioblastomas and that seem to be specific for this tumor stage are loss of heterozygosity of chromosome 10 along with EGF receptor up-regulation that may be one of the factors that contributed to the up-regulation of COX-2 (9, 29, 40) .
Consistent with the findings of Onguru et al (27) , Joki et al. (14) and Deininger et al. (5), we observed significant COX-2 staining within astrocytic tumor cells located predominantly but not exclusively around areas of necrosis. This distribution may represent induction of COX-2 by hypoxia or hypoglucosemia, as has been observed for ischemia (31) and trauma (16, 23) and is consistent with the inducibility of COX-2. However, we also observed COX-2 staining at sites without necrosis, suggesting that COX-2 may be constitutively expressed in tumor cells. We did not observe any COX-2 staining in the nuclei of tumor cells as that reported by Shono et al (35) . Its significance is unclear, but this observation may represent the known distribution of COX-2 within the nuclear membrane. COX-2 expression did not show significant difference among patient age, sex and tumor location as observed by Shono et al. (35) and Lee et al (20) .
In the present study, we found a significant positive correlation between COX-2 expression and the angiogenetic factor VEGF expression and MVD in astrocytomas. Our results are supported by previous reports of Hara et al. (13) and Marina et al. (22) , who found a strong correlation among the expression of these markers in astrocytomas. Tsuji et al. (39) demonstrated that COX-2 stimulates colon cancer cells to release pro-angiogenic PGs that promote endothelial cell migration and tube formation, and these effects can be blocked by NS-398, a selective inhibitor of COX-2. Samaras and others reported that the coordinate expression and topographical relationship of IL-6, IL-8, COX-2, and VEGF in the same tumor areas (e.g., perinecrotic areas) attest to their intimate liaison in terms of cancer-induced angiogenesis, which is probably secondary to the induction of multiple interdependent molecular pathways (32) . Moreover, Majima et al. (21) considered endogenous PGs might increase cAMPfacilitated angiogenesis through induction of VEGF in a rat sponge implantation model. These data suggest that COX-2 participates in the induction of VEGF or, alternatively, COX-2 and VEGF may have a common induction pathway. On the other hand, Onguru et al. (27) , found no correlation between COX-2 expression and MVD in glioblastomas.
In the present study, COX-2 overexpression was significantly correlated with poor survival. Several studies have similarly provided evidence of a relationship between shortened survival and elevated COX-2 expression (13, 20, 22, 35) . Sawaoka et al. (31) have demonstrated that oral administration of specific COX-2 inhibitors lowered the expression of VEGF, reduced angiogenesis and growth, induced apoptosis, and suppressed cell replication of the COX-2 overexpressing gastrointestinal cancer xenografts in a dose-dependent manner. Joki et al. (14) , demonstrated that NS-398, a COX-2 specific inhibitor, can increase apoptosis, reduce proliferation, and attenuate invasion of cultured human glioma cells. This indicates that COX-2 inhibitors may represent an important therapeutic target in the treatment of astrocytomas, particularly if the selective COX-2 inhibitor can cross the blood brain barrier.
In conclusion, a stepwise increase in COX-2 expression from low grade to high grade astrocytomas might suggest the role of COX-2 in tumor progression. The close correlation between COX-2 expression, VEGF expression and MVD, raises the possibility that the COX-2 pathway may contribute to astrocytic tumorigenesis by promoting new vessel formation. Increased COX-2 expression is a significant negative predictor of survival in astrocytic tumors. This will help to establish a comprehensive therapeutic measure of patients and provide a new approach to tumor therapy through COX-2 inhibitors. We join Perdiki and his colleagues (29) and call for further studies to investigate the clinical usefulness of COX-2 inhibitors in the treatment of astrocytoma.
